Hyperadrenergic Postural Tachycardia Syndrome: Clinical Biomarkers and Response to Guanfacine.
Okamoto LE, Urechie V, Rigo S, Abner JJ, Giesecke M, Muldowney JAS, Furlan R, Shibao CA, Shirey-Rice JK, Pulley JM, Diedrich A, Biaggioni I.
Okamoto LE, et al.
Hypertension. 2024 Nov;81(11):2237-2247. doi: 10.1161/HYPERTENSIONAHA.124.23035. Epub 2024 Aug 7.
Hypertension. 2024.
PMID: 39109428
Free PMC article.
BACKGROUND: A subset of patients with postural tachycardia syndrome (POTS) are thought to have a primary hyperadrenergic cause. We assessed clinical biomarkers to identify those that would benefit from sympatholytic therapy. METHODS: We measured sympathetic function …
BACKGROUND: A subset of patients with postural tachycardia syndrome (POTS) are thought to have a primary hyperadrenergic cause …